Amy Rappaport

Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly reactive antibodies against seasonal influenza A viruses

Spencer R. Pierce, Hua Shi, Camila Carla da Silva Caetano, David A Prots et autres

us (code pays fourni par la source)

Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist

Amy Rappaport, Elena Bekerman, Gregory R. Boucher, Janette Sung et autres

While therapeutic vaccines are a promising strategy for inducing human immunodeficiency virus (HIV) control, HIV vaccines tested to date have offered limited benefit to people living with HIV. The barriers to success may include the use of vaccine platforms and/or immunogens that …

us (code pays fourni par la source)

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results

Amy Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart et autres

us (code pays fourni par la source)

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults

Christine D. Palmer, Ciaran D. Scallan, Lauren D. Kraemer Tardif, Melissa A. Kachura et autres

SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying …

gb, it, bd (code pays fourni par la source)

Abstract 2267: HLA-DR-restricted CD4 T cell responses to KRAS G12C in healthy donors linked to bacterial mimotope: lessons for KRAS neoantigen vaccines in cancer patients

Christine D. Palmer, Meghan G. Hart, Sonia Kounlavouth, Harshni Venkatraman et autres

Abstract Mutations in the KRAS gene are among the most common driver mutations in cancer. Targeting KRAS G12C mutations has shown some promise in clinical studies, though acquired resistance mutations pose a challenge for small molecule-based monotherapies. Vaccines targeting KRAS mutations remain …

us (code pays fourni par la source)

Figure S1 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Fig. S1, related to Figs 1 & 2. Tumor histology across genotypes at 8-16 weeks after Adeno-Cre infection.

Figure S5 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Fig. S5, related to Fig. 5.

Supplementary Tables from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Supplementary Tables

Supplementary Data from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Supplementary Legends, Materials and Methods

Figure S3 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Fig. S3, related to Fig. 3.

Figure S2 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Fig. S2, related to Fig. 2.

Figure S4 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang‐Min Jeon et autres

Fig. S4, related to Fig. 4.